Richard Pazdur

TL;DR: The most common adverse reactions with PTD were alopecia, diarrhea, nausea, and neutropenia, while the pathologic complete response rates by the FDA-preferred definition of invasive cancer in the breast and lymph nodes were 39.3% and 21.5% in the PTD and the TD arms, respectively.

TL;DR: Eculizumab was studied in a randomized, double-blind, placebo-controlled clinical trial in 87 RBC transfusion-dependent adult PNH patients and in a supportive single-arm study in 96 patients, with significant findings included the development of human anti-human antibody responses in three patients and serious meningococcal infections inThree patients.

TL;DR: The U.S. Food and Drug Administration granted accelerated approval for nivolumab for the treatment of patients with classical Hodgkin L that has relapsed or progressed after autologous HSCT and post‐transplantation brentuximab vedotin on May 17, 2016.

TL;DR: Ruxolitinib treatment was associated with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia and is the first drug approved for myelofibrosis.

TL;DR: The purpose of this report is to summarize information on pemetrexed (LY231514; MTA; Alimta; Eli Lilly and Company; Indianapolis, IN), a drug recently approved by the U.S. Food and Drug Administration (FDA).